Table 2 Baseline characteristics of subjects treated with either rituximab or cyclophosphamide and stratified by primary endpoint outcome
Rituximab | p Value | Cyclophosphamide | p Value | |||
|---|---|---|---|---|---|---|
Success, n = 60 | Failure, n = 34 | Success, n = 48 | Failure, n = 45 | |||
Age | 53.25 | 56 | 0.44 | 51.3 | 51.9 | 0.85 |
Sex | 0.52 | 0.68 | ||||
Male | 45 % | 53 % | 50 % | 56 % | ||
Female | 55 % | 47 % | 50 % | 44 % | ||
ANCA-associated vasculitis type | 0.66 | 0.27 | ||||
PR3 | 67 % | 62 % | 60 % | 66 % | ||
MPO | 33 % | 38 % | 40 % | 34 % | ||
Newly diagnosed at enrollment | 48 % | 50 % | 1.0 | 56 % | 36 % | 0.06 |
BVAS/WG | 7.97 ± 0.36 | 8.09 ± 0.52 | 0.85 | 8.42 ± 0.53 | 7.60 ± 0.47 | 0.25 |